HPC › Nutrition › Glossary
Curcumin is the principal polyphenolic compound in turmeric (Curcuma longa), responsible for its characteristic yellow colour. It suppresses inflammatory signalling by inhibiting nuclear factor-kappa B (NF-kB) activation and reducing pro-inflammatory cytokines including IL-6 and TNF-alpha. Poor oral bioavailability, caused by rapid intestinal metabolism and systemic clearance, limits clinical translation of its considerable in vitro promise.
Commercial supplements labelled 'curcumin' typically contain a standardised extract comprising 95% curcuminoids, which includes curcumin alongside demethoxycurcumin and bisdemethoxycurcumin.
How it works
Curcumin exerts its anti-inflammatory effect through two converging molecular pathways. The first centres on nuclear factor-kappa B (NF-kB): curcumin prevents phosphorylation and subsequent degradation of IkBa, the inhibitory protein that holds NF-kB sequestered in the cytoplasm. Without that degradation step, the p65 subunit cannot translocate to the nucleus to transcribe genes encoding IL-6, TNF-alpha, and cyclo-oxygenase-2 1. Curcumin simultaneously activates the Nrf2/ARE pathway, upregulating cytoprotective enzymes including haem oxygenase-1 (HO-1) and NQO-1, which reduces oxidative burden through a mechanism independent of NF-kB 1.
The central constraint on translating this mechanism into clinical benefit is poor oral bioavailability 2. After ingestion, curcumin undergoes rapid conjugation and reduction in the intestinal wall and liver, generating glucuronide and sulphate conjugates rather than free compound in the bloodstream. Phase I trials detect negligible serum curcumin even at 12 g per day, confirming the intestinal barrier is largely impermeable to unmodified curcumin 2. Co-administration of piperine, the alkaloid from black pepper, partially overcomes this by inhibiting intestinal glucuronidation: 20 mg alongside 2 g of curcumin increased serum area-under-the-curve by approximately 2,000% in a controlled human study, though the control arm measured below the detection limit, meaning the ratio describes an extreme low baseline rather than a simple doubling 3.
Example
An athlete managing persistent low-grade joint inflammation adds a standard 500 mg curcumin capsule to their daily protocol. After six weeks, inflammatory markers remain unchanged. On review, the formulation contains neither piperine nor a phospholipid carrier. Switching to a bioavailability-enhanced product combining 500 mg curcumin with 20 mg piperine at the same cost produces a measurable reduction in joint stiffness and C-reactive protein within a comparable intervention window.
Formulation matters as much as dose; unmodified curcumin rarely reaches plasma at concentrations sufficient to engage its anti-inflammatory targets.
Why it matters
Curcumin occupies a contested but credible position in evidence-based nutrition. A meta-analysis of randomised controlled trials found supplementation at doses up to 1,000 mg per day produced statistically significant reductions in serum C-reactive protein compared with placebo, with larger effect sizes after interventions exceeding ten weeks 5. Used in bioavailability-enhanced form, curcumin represents a non-pharmaceutical option for managing low-grade systemic inflammation, particularly in populations with rheumatoid arthritis or ulcerative colitis where supplementation studies report significant reductions in both CRP and erythrocyte sedimentation rate 5.
The case for caution is also substantive. Nelson et al. classified curcumin as chemically unstable and highly reactive in aqueous solution, arguing that many reported in vitro effects may reflect non-specific artefacts rather than genuine target engagement 4. Despite more than 120 clinical trials, no double-blinded placebo-controlled study has demonstrated unambiguous therapeutic success, with the preclinical-clinical gap attributed primarily to the bioavailability problem 4. Curcumin has sufficient clinical evidence to justify use as an anti-inflammatory adjunct; it does not yet have enough to warrant treatment as an established therapeutic.
Does curcumin actually work in humans?+
The evidence is mixed. A meta-analysis of randomised controlled trials found curcumin supplementation at up to 1,000 mg per day significantly reduced C-reactive protein compared with placebo. However, no double-blinded placebo-controlled trial has demonstrated unambiguous therapeutic efficacy, and some researchers classify curcumin as chemically unsuitable for drug development due to instability in aqueous solution.
How do you increase curcumin absorption?+
The most evidence-backed strategy is co-administering 20 mg of piperine (from black pepper extract) with each curcumin dose. Piperine inhibits intestinal glucuronidation, the main metabolic process that clears curcumin before it reaches systemic circulation. Phospholipid complexes and nanoparticle encapsulation are alternatives used in clinical research when piperine co-administration is not practical.
What is curcumin's primary anti-inflammatory mechanism?+
Curcumin suppresses the NF-kB signalling pathway by blocking degradation of IkBa, the protein that normally prevents NF-kB from entering the cell nucleus. This stops transcription of genes encoding pro-inflammatory cytokines including IL-6 and TNF-alpha. Curcumin also activates the Nrf2/ARE pathway, upregulating antioxidant enzymes as a secondary cytoprotective mechanism.
What dose of curcumin reduces inflammation?+
Randomised controlled trials reporting significant reductions in C-reactive protein have predominantly used doses between 250 mg and 1,000 mg per day over 8 to 12 weeks. Effect size improves with intervention duration beyond ten weeks. Bioavailability-enhanced formulations may achieve equivalent effects at lower doses, though direct dose-equivalence studies across formulation types are limited.
